Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O95749
UPID:
GGPPS_HUMAN
Alternative names:
(2E,6E)-farnesyl diphosphate synthase; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Farnesyltranstransferase; Geranylgeranyl diphosphate synthase; Geranyltranstransferase
Alternative UPACC:
O95749; A8MVQ8; Q5T2C8; Q6NW19
Background:
Geranylgeranyl pyrophosphate synthase, known by alternative names such as farnesyl diphosphate synthase and geranyltranstransferase, plays a pivotal role in the biosynthesis of geranylgeranyl pyrophosphate. This compound is a crucial precursor for carotenoids and geranylated proteins, essential for cellular function and integrity.
Therapeutic significance:
The protein is linked to Muscular dystrophy, congenital hearing loss, and ovarian insufficiency syndrome, a disorder marked by muscle weakness, hearing loss, and ovarian insufficiency. Understanding the role of Geranylgeranyl pyrophosphate synthase could open doors to potential therapeutic strategies for this syndrome.